Every 10-Q that NVE Corp (NVEC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow NVEC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NVEC filings page.
NVE Corporation reported higher revenue and earnings for the quarter ended June 30, 2026, the first quarter of fiscal 2027. Total revenue was $11,034,057, up 81% from the prior-year quarter, driven by an 82% increase in product sales to $10,734,735 and higher contract R&D revenue. Gross profit was $8,968,012, an 81.3% margin.
Operating expenses rose to $1,702,176 as the company increased research and development and performance-based compensation. Net income was $6,394,191, or $1.32 per diluted share, up from $3,575,818, or $0.74, a year earlier. Cash from operating activities was $5,306,318, and cash and cash equivalents were $2,896,148. Total assets were $62,116,940, with marketable securities and money market funds representing approximately 69% of total assets.
The company paid a $1.00 cash dividend per share in the quarter and subsequently declared another $1.00 dividend payable August 31, 2026. Management reports effective disclosure controls, no material legal proceedings, and no material changes to previously disclosed risk factors.
NVE Corporation’s quarterly report shows solid third-quarter growth but softer results for the fiscal year to date. For the quarter ended December 31, 2025, revenue rose to $6.2 million from $5.1 million, driven by higher product sales and a sharp increase in contract research and development revenue. Quarterly net income increased to $3.4 million, or $0.70 per diluted share, compared with $3.0 million and $0.63 a year earlier.
For the first nine months of fiscal 2026, revenue was nearly flat at $18.7 million, while net income declined to $10.3 million from $11.2 million as gross margin slipped from 85% to 79% due to a less profitable product mix and more distributor sales. The company remained highly liquid, with $3.4 million in cash and $43.6 million in marketable securities, representing about 73% of total assets, and shareholders’ equity of $58.3 million against minimal liabilities.
NVE continued an aggressive cash-return policy, paying $3.00 per share in dividends during the first nine months and declaring another $1.00 per share dividend payable February 27, 2026. The report adds a new risk factor on higher employment costs from Minnesota’s paid leave law and notes that a key Supplier Partnering Agreement with Abbott Laboratories now runs through December 31, 2027.
NVE Corporation filed its quarterly report, posting Q2 FY2026 revenue of $6,346,992 and net income of $3,310,838, or $0.68 per diluted share. Gross margin was 78% of revenue.
Revenue decreased 6% year over year as contract R&D fell 68%, partially offset by a 1% rise in product sales. Operating expenses declined 7%, and interest income was $484,330. The effective tax rate rose to 20%.
Cash and cash equivalents were $5,107,481, with money market funds and marketable securities totaling $45,226,523 and representing approximately 74% of total assets of $61,490,218. The company paid $1.00 per share in dividends during the quarter and subsequently declared another $1.00 dividend payable November 28, 2025. Shares outstanding were 4,837,166 as of September 30, 2025.